SURVYR

RLAY

Relay Therapeutics, Inc.
$19.69
+$0.85 (4.51%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-19%+33%+84%+136%+188%Oct 2025Oct 2026Apr 202652w high $21.2752w low $5.95
RLAYSPY
Wall St. Highest PT $32.00 (+62.5%) Wall St. Avg PT $27.58 (+40.1%)
$6$13$20$26$33POC $19Hi $32Avg $28
Underwater Drawdown %Max DD -28.2%Current -5.1%
0.0%-28.2%
Relative Strength vs SPY+152.9% vs SPYOutperforming
+196%0%-196%
1W
+$1.28 (6.95%)
1M
+$2.00 (11.31%)
3M
+$1.32 (7.19%)
6M
+$7.12 (56.64%)
YTD
+$11.23 (132.74%)
1Y
+$12.17 (161.84%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
13 analysts · mean score 1.23
1 = Strong Buy · 5 = Sell
Strong Buy1077%
Buy323%
Hold00%
Underperform00%
Sell00%
Wall Street consensus · as of Oct 8, 2026
Analyst price targets
Current price$19.69
Average target$27.58
+$7.89 (+40.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$20.00
Median$27.50
High$32.00
12-month Wall Street target range · as of Oct 8, 2026

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$4.0B
P/E (next 12 months, estimated)-11.3
52-week range$5.95 – $21.27
Revenue growth (latest quarter vs a year ago)-48.3%
Dividend yieldNo dividend
Analyst consensusStrong Buy (12)
Average analyst price target$27.58 (+40%)

What they do

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for RLAY yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Held by 1 of 7 live models: New Highs Growth.

New Highs Growth
4.0% of the book
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book
Why it's in the New Highs Growth

Qualified on Biotech, -13% from 52-week high, biotech, price-only entry, 12-1 momentum +254%.

What would knock it out: Drops out if it falls outside the top 25 at the next rebalance (Oct 30). In the latest preview (2026-10-28) it ranks 3rd.

Earnings & events

RLAY earningsNext report in 7 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Time not confirmed
EPS consensus-$0.40
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.41est -$0.39−4.4%Below estimates
May 5, 2026-$0.41est -$0.36−15.0%Below estimates
Feb 26, 2026-$0.31est -$0.40+21.7%Above estimates
Nov 6, 2025-$0.43est -$0.42−2.8%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-27 17:57:30 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.780.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
No recent headlines.

Research

New Highs Growth: rebalance of Sep 30, 2026Oct 22, 2026
Insider trades
Patel Sanjiv
Director, President and CEO · 2026-10-07
Sell
$872.4K
Catinazzo Thomas
Chief Financial Officer · 2026-10-06
Sell
$4.0K
Catinazzo Thomas
Chief Financial Officer · 2026-10-06
Sell
$325.4K
Patel Sanjiv
Director, President and CEO · 2026-09-08
Sell
$912.9K
Catinazzo Thomas
Chief Financial Officer · 2026-09-08
Sell
$335.6K
Bergstrom Donald A
President, R&D · 2026-09-08
Sell
$161.8K
Rahmer Peter
See remarks · 2026-08-26
Sell
$90.3K
Svf Pauling (Cayman) Ltd
10% owner · 2026-08-25
Sell
$116.4M
Patel Sanjiv
Director, President and CEO · 2026-08-17
Sell
$979.9K
Catinazzo Thomas
Chief Financial Officer · 2026-08-14
Sell
$349.7K
Bergstrom Donald A
President, R&D · 2026-07-28
Sell
$41.6K
Rahmer Peter
See remarks · 2026-07-28
Sell
$13.9K

Stats refreshed 2026-10-27 17:57:30 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026